X

Trial Profile

The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression (P-TRD)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Sep 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Psilocybin (Primary)
Indications Depression; Major depressive disorder
Focus Therapeutic Use
Acronyms P-TRD
Sponsors COMPASS Pathways

Most Recent Events

08 Dec 2022 According to a COMPASS Pathways media release, results from this trial were presented at the Annual Meeting of the American College of Neuropsychopharmacology (ACNP) 2022.
03 Nov 2022 Results for changes in positive and negative affect, anxiety, functioning, quality of life, and cognition, published in the COMPASS Pathways Media Release
03 Nov 2022 Results published in the New England Journal of Medicine.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com